Effect of pancreatic kallikrein combined with magnesium sulfate therapy on disease severity of patients with severe preeclampsia
Objective: To study the clinical effect of pancreatic kallikrein combined with magnesium sulfate therapy on severe preeclampsia. Methods: A total of 47 patients with severe preeclampsia treated in our hospital from May 2013 to October 2015 were retrospectively analyzed, patients who received panc...
Main Author: | |
---|---|
Format: | Article |
Language: | English |
Published: |
Editorial Board of Journal of Hainan Medical University
2016-10-01
|
Series: | Journal of Hainan Medical University |
Subjects: | |
Online Access: | http://www.hnykdxxb.com/PDF/201619/28.pdf |
id |
doaj-269b77534e5c4696848e686ebf2c72b8 |
---|---|
record_format |
Article |
spelling |
doaj-269b77534e5c4696848e686ebf2c72b82020-11-25T00:25:00ZengEditorial Board of Journal of Hainan Medical UniversityJournal of Hainan Medical University1007-12371007-12372016-10-012219105108Effect of pancreatic kallikrein combined with magnesium sulfate therapy on disease severity of patients with severe preeclampsiaYi Yang0Department of Gynecology and Obstetrics, Zigong Maternal and Child Health Care Hospital of Sichuan Province, Zigong City, Sichuan Province, 643000, ChinaObjective: To study the clinical effect of pancreatic kallikrein combined with magnesium sulfate therapy on severe preeclampsia. Methods: A total of 47 patients with severe preeclampsia treated in our hospital from May 2013 to October 2015 were retrospectively analyzed, patients who received pancreatic kallikrein combined with magnesium sulfate therapy were selected as observation group, patients who received magnesium sulfate therapy were selected as control group, and then blood pressure level, renal function, uterine artery and umbilical artery blood flow state, and hypoxia indexes in serum and placenta were compared between two groups. Results: After treatment, systolic pressure and diastolic pressure levels as well as serum CysC level and 24 h urine protein level of observation group were significantly lower than those of control group, the uterine artery and umbilical artery S/ D and PI were significantly lower than those of control group, PIGF and NO levels in serum as well as Xiap and Survivin levels in placenta were significantly higher than those of control group, and sVEGFR1 level in serum as well as Caspase-3 and Caspase-7 levels in placenta was significantly lower than those of control group. Conclusions: Pancreatic kallikrein combined with magnesium sulfate therapy can alleviate the disease severity, lower blood pressure and vascular resistance, and improve renal function and the apoptosis caused by placental hypoxia in patients with severe preeclampsia.http://www.hnykdxxb.com/PDF/201619/28.pdfPreeclampsiaPancreatic kallikreinPlacentaHypoxiaApoptosis |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Yi Yang |
spellingShingle |
Yi Yang Effect of pancreatic kallikrein combined with magnesium sulfate therapy on disease severity of patients with severe preeclampsia Journal of Hainan Medical University Preeclampsia Pancreatic kallikrein Placenta Hypoxia Apoptosis |
author_facet |
Yi Yang |
author_sort |
Yi Yang |
title |
Effect of pancreatic kallikrein combined with magnesium sulfate therapy on disease severity of patients with severe preeclampsia |
title_short |
Effect of pancreatic kallikrein combined with magnesium sulfate therapy on disease severity of patients with severe preeclampsia |
title_full |
Effect of pancreatic kallikrein combined with magnesium sulfate therapy on disease severity of patients with severe preeclampsia |
title_fullStr |
Effect of pancreatic kallikrein combined with magnesium sulfate therapy on disease severity of patients with severe preeclampsia |
title_full_unstemmed |
Effect of pancreatic kallikrein combined with magnesium sulfate therapy on disease severity of patients with severe preeclampsia |
title_sort |
effect of pancreatic kallikrein combined with magnesium sulfate therapy on disease severity of patients with severe preeclampsia |
publisher |
Editorial Board of Journal of Hainan Medical University |
series |
Journal of Hainan Medical University |
issn |
1007-1237 1007-1237 |
publishDate |
2016-10-01 |
description |
Objective: To study the clinical effect of pancreatic kallikrein combined with magnesium
sulfate therapy on severe preeclampsia. Methods: A total of 47 patients with severe
preeclampsia treated in our hospital from May 2013 to October 2015 were retrospectively
analyzed, patients who received pancreatic kallikrein combined with magnesium sulfate
therapy were selected as observation group, patients who received magnesium sulfate therapy
were selected as control group, and then blood pressure level, renal function, uterine artery
and umbilical artery blood flow state, and hypoxia indexes in serum and placenta were
compared between two groups. Results: After treatment, systolic pressure and diastolic
pressure levels as well as serum CysC level and 24 h urine protein level of observation group
were significantly lower than those of control group, the uterine artery and umbilical artery S/
D and PI were significantly lower than those of control group, PIGF and NO levels in serum
as well as Xiap and Survivin levels in placenta were significantly higher than those of control
group, and sVEGFR1 level in serum as well as Caspase-3 and Caspase-7 levels in placenta was
significantly lower than those of control group. Conclusions: Pancreatic kallikrein combined
with magnesium sulfate therapy can alleviate the disease severity, lower blood pressure and
vascular resistance, and improve renal function and the apoptosis caused by placental hypoxia
in patients with severe preeclampsia. |
topic |
Preeclampsia Pancreatic kallikrein Placenta Hypoxia Apoptosis |
url |
http://www.hnykdxxb.com/PDF/201619/28.pdf |
work_keys_str_mv |
AT yiyang effectofpancreatickallikreincombinedwithmagnesiumsulfatetherapyondiseaseseverityofpatientswithseverepreeclampsia |
_version_ |
1725350430220746752 |